Viyash Scientific Limited Completes Distribution of Fractional Share Proceeds
Viyash Scientific Limited has completed the distribution of sale proceeds from fractional shares to eligible shareholders. The fractional shares were sold on February 27, 2026, and proceeds were distributed on March 6 and March 9, 2026, as per the composite scheme of amalgamation.
This is a procedural update regarding the distribution of proceeds from fractional shares resulting from a past corporate action. It does not introduce new financial performance indicators or strategic shifts.
The announcement is a routine update on the completion of a process related to a past amalgamation scheme, with no new financial or strategic information provided.
Viyash Scientific Limited (formerly Sequent Scientific Limited) has reported the completion of the distribution of proceeds from the sale of fractional shares to its eligible shareholders. This action is pursuant to a composite scheme of amalgamation involving Viyash Scientific Limited and several other entities.
The National Company Law Tribunal (NCLT), Hyderabad bench, had approved and sanctioned the scheme on November 18, 2025, with the scheme becoming effective on December 16, 2025. Eligible equity shareholders as of the record date, December 8, 2025, were allotted equity shares of Viyash Scientific Limited on December 16, 2025. A total of 18,19,21,827 equity shares were allotted, including 13 shares in lieu of fractional entitlements.
PNB Investment Services Limited was appointed as the trustee to hold these fractional shares. The fractional shares were sold in the open market on February 27, 2026, within 90 days of allotment. The net proceeds from this sale have been distributed to the eligible fractional shareholders on March 6, 2026, and March 9, 2026. The Audit Committee and Independent Directors have certified that this distribution was conducted in accordance with the Scheme and SEBI Master Circular.
What to do with a filing like this
Viyash Scientific Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Viyash Scientific Limited. Read the original for the full detail.